Financial Results and Press Release for the Quarter ended 30 June 2026
RESULTS
▲ Positive Development
MEDIUM RISK
📅 Filed on BSE: 30 Jul 2026, 11:24 AM IST · BSE ID: afcc1f33-51b3-4bb8-8185-7e2b4ceb2f66
View Original BSE Filing (PDF)
💡
In Simple Terms
Hester Biosciences' profit increased significantly in the latest quarter due to higher sales, while consolidated profit included a large exceptional gain.
🤖 AI Summary
- Standalone Profit After Tax increased 87.69% to INR 147.11 Million for the quarter ended 30 June 2026 (Q1 FY27).
- Revenue from Operations for the standalone entity grew 14.45% YoY to INR 726.60 Million in Q1 FY27.
- Standalone Earnings Per Share (Basic & Diluted) was INR 17.29 for the quarter ended 30 June 2026.
- Consolidated Profit After Tax for Q1 FY27 was INR 967.32 Million, including exceptional items of INR 853.49 Million.
- The Board of Directors approved both the unaudited standalone and consolidated financial results for Q1 FY27.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Standalone Revenue from Operations
726.60 Million
14.45%
Standalone Profit after tax
147.11 Million
87.69%
Standalone Earnings Per Share (Basic & Diluted)
17.29 (INR)
87.73%
Consolidated Profit after tax
967.32 Million
459.86%
Consolidated Earnings Per Share (Basic & Diluted)
113.71 (INR)
459.32%
🏢 How This Affects the Company
Standalone revenue from Poultry Healthcare increased to INR 618.16 Million in Q1 FY27 from INR 416.68 Million in Q1 FY26, suggesting stronger performance in this segment. Animal Healthcare segment revenue decreased to INR 108.44 Million from INR 218.22 Million year-on-year.
Standalone Profit After Tax for Q1 FY27 rose to INR 147.11 Million from INR 78.38 Million in Q1 FY26. Consolidated Profit After Tax was INR 967.32 Million, significantly boosted by INR 853.49 Million in exceptional items.
Segment results for Poultry Healthcare increased to INR 245.19 Million in Q1 FY27 from INR 89.69 Million in Q1 FY26. Animal Healthcare segment reported a loss of INR (8.47) Million, compared to a profit of INR 35.25 Million in Q1 FY26.
👥 What This Means For Shareholders
✅
Action Required
No action is required from shareholders based on this financial results filing.
👤
Who Is Affected
All shareholders are affected by the company's financial performance, with Q1 FY27 standalone EPS at INR 17.29 and consolidated EPS at INR 113.71.
🔍
Management Signal
The Board's approval of the unaudited financial results signals regular compliance with SEBI regulations and transparent disclosure of quarterly performance.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Q2 FY27 results — observe Animal Healthcare segment performance trends.
Further updates on utilization of funds from exceptional items (if applicable).
Any future communication regarding segment-wise strategic initiatives.
MEDIUM RISK
Consolidated profit is heavily reliant on a large exceptional item; Animal Healthcare segment faces declining revenue and a loss.
💡 Investor Takeaway
Hester Biosciences reported standalone Profit After Tax of INR 147.11 Million in Q1 FY27, an 87.69% increase year-on-year, on revenue of INR 726.60 Million. Consolidated PAT was INR 967.32 Million, largely due to INR 853.49 Million in exceptional items. Poultry Healthcare segment revenue improved, while Animal Healthcare declined.
⚖️ Strengths & Concerns
✅ Positives
- Standalone Profit After Tax increased 87.69% to INR 147.11 Million in Q1 FY27 from INR 78.38 Million in Q1 FY26.
- Standalone Revenue from Operations grew 14.45% to INR 726.60 Million in Q1 FY27 compared to INR 634.90 Million in Q1 FY26.
⚠️ Concerns
- Standalone Animal Healthcare segment revenue decreased 50.31% to INR 108.44 Million in Q1 FY27 from INR 218.22 Million in Q1 FY26.
- Standalone Animal Healthcare segment recorded a loss of INR (8.47) Million in Q1 FY27, compared to a profit of INR 35.25 Million in Q1 FY26.
📅 Company Track Record
Hester Biosciences reported standalone PAT of INR 521.00 Million for FY26, a 64% increase year-on-year, and proposed an INR 11 dividend. The company also divested 43.81% equity in Texas Lifescience Private Limited, which ceased to be a subsidiary from March 27, 2026.
Based on publicly available historical data. For context only.
❓ Frequently Asked Questions
What was Hester Biosciences' standalone net profit for Q1 FY27?
Hester Biosciences reported a standalone Profit After Tax of INR 147.11 Million for the quarter ended 30 June 2026.
How much did Hester Biosciences' standalone revenue from operations grow in Q1 FY27?
Standalone Revenue from Operations for Hester Biosciences grew 14.45% year-on-year to INR 726.60 Million in Q1 FY27.
What was the consolidated profit after tax for Hester Biosciences in Q1 FY27?
Consolidated Profit After Tax for Hester Biosciences was INR 967.32 Million for the quarter ended 30 June 2026, which includes INR 853.49 Million in exceptional items.
What were the segment results for Hester Biosciences' Poultry Healthcare in Q1 FY27?
The Poultry Healthcare segment reported results of INR 245.19 Million for the quarter ended 30 June 2026.
What was Hester Biosciences' standalone Earnings Per Share (EPS) for Q1 FY27?
Standalone Earnings Per Share (Basic & Diluted) for Hester Biosciences was INR 17.29 for the quarter ended 30 June 2026.
Questions based on this BSE filing only. For information purposes.